Abstract: A system and method for producing hydrogen wherein the system comprises at least one electrolyzer adapted to be located within a subterranean formation, at least one electrical supply cable having a length selected to extend from the at least one electrolyzer to a ground surface power supply, at least one supply tubing string having a length selected to extend from the at least one electrolyzer to a water supply at the ground surface and at least one collection tubing string having a length selected to extend from the at least one electrolyzer to a collection location at the ground surface. The method comprises providing a well from a surface to an underground formation, locating at least one electrolyzer in the well, supplying the at least one electrolyzer with supply electricity, supplying the at least one electrolyzer with supply water, producing hydrogen gas at the electrolyzer and collecting and transporting the produced hydrogen gas to the surface.

Abstract: A method for enhancing geothermal recovery in a subterranean heat reservoir is disclosed. The method comprises determining a thermal pathway stress load and a pore pressure; selecting a target thermal conductivity and target dimensions of the thermal pathway; selecting a volume of thermal particles; selecting a volume of carrier fluid; mixing the selected volume of thermal particles and the selected volume of carrier fluid to produce the slurry; injecting the slurry into the openings in the subterranean heat reservoir; and closing the openings containing the slurry to form the thermal pathway. Also disclosed are methods for producing a slurry for enhancing geothermal recovery in a subterranean heat reservoir and for preparing a volume of thermal particles for enhancing geothermal recovery in a subterranean heat reservoir. The resulting thermal pathway according to the embodiments of the present disclosure can enhance the geothermal energy recovery over a long period of time.

Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug thereof, a pharmaceutical composition and a pill container comprising same, a preparation method therefor, and the use thereof in the preparation of drugs for preventing or treating STING-mediated related diseases.

Abstract: Implementations relate to treatment of a petroleum reservoir to produce a hydrogen-bearing gas. Implementations may include methods and systems for processing a reservoir to generate hydrogen in-situ and produce a large fraction of the generated hydrogen to the surface. Processing the reservoir may include injecting oxygen into the reservoir to enable combustion within the reservoir to create heat and carbon monoxide in the reservoir. The heat may generate steam from both boiling of in-situ formation water and steam generated from the oxidation reactions. The generated heat may enable gasification, steam reforming, and aquathermolysis reactions and both the heat and carbon monoxide enables the water-gas shift reaction. Each such reaction may generate hydrogen within the reservoir.

Abstract: The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-FXI/FXIa antibody or antigen-binding fragment thereof described in the present invention has specificity and high affinity to FXI/FXIa, and can effectively inhibit the activity of FXI/FXIa. Therefore, the present invention further provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in the preparation of a drug which is used for the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism.

Abstract: A bandwidth part (BWP) switching method is performed by a base station. The method includes: sending timing indication information, wherein the timing indication information indicates configuration of timing information, and the timing information is used for user equipment (UE) to determine a related operation of BWP switching according to a specified duration indicated by the timing information.

Abstract: Provided are an anti-Nectin-4 antibody or antigen-binding fragment thereof, an antibody conjugate comprising the same, and use thereof in the manufacture of a medicament, particularly in the manufacture of a medicament for treating and/or preventing cancer.

Abstract: The present application relates to a method for improving the product quality of an antibody-drug conjugate. The method comprises: conjugating a drug to be conjugated to an antibody to obtain an antibody-drug conjugate; and purifying the antibody-drug conjugate: a regulation solution is added to the antibody-drug conjugate, column chromatography flowthrough is performed to collect a product, and the product is further subjected to ultrafiltration and/or diafiltration concentration to obtain an antibody-drug conjugate with improved product quality. The obtained antibody-drug conjugate has high purity, a uniform DAR, no solvent residue, and stable quality. Moreover, the pretreatment of the antibody does not involve steps such as ultrafiltration and diafiltration, which simplifies antibody purification and reduces production costs.

Abstract: An anti-PD-1 antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-PD-1 antibody or the antigen-binding fragment thereof has high specificity and high affinity to PD-1, and can effectively block the binding of PD-1/PD-L1 and PD-1/PD-L2 so as to activate the immune system, thereby achieving the effect of inhibiting tumor growth. Therefore, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof and a use of the pharmaceutical composition in preparation of drugs are further comprised. The drugs are used for preventing and/or treating tumors, infections, or autoimmune diseases.

Abstract: Disclosed in the present invention is the use of an anti-HER2 antibody-drug conjugate in cancer treatment. Further provided in the present invention is the use of a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of each of the foregoing in the manufacture of a medicament for the prophylaxis and/or treatment of a cancer insensitive or irresponsive to a treatment with a HER2-targeting agent.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: Automatic file system capacity management techniques are provided using file system utilization prediction. One method comprises obtaining input data representing a utilization of a storage capacity of a file system of a given storage system; predicting a future utilization of the storage capacity of the file system based on a portion of the obtained input data; and automatically adjusting the storage capacity of the file system based at least in part on a result of a comparison of the predicted utilization of the storage capacity to a current utilization of the storage capacity. The comparison of the predicted utilization to a current utilization of the storage capacity may comprise comparing the current utilization of the storage capacity to the predicted utilization of the storage capacity for at least first and second time periods following a current time period to determine a trend of the utilization of the storage capacity.

Abstract: Storage processes are described. For instance, dumping of cache data in a memory table at a source directory table partition in a source container group is stopped in response to receiving a close signal. A notification for creating a target directory table partition is sent to a target container group, the notification including a checkpoint at the source directory table partition. The cache data in the memory table is sent to the target container group, and the source container group is closed in response to a determination that an ownership of the target directory table partition is updated to the target container group. A rescheduling and/or upgrading solution is thus proposed for a source container group, so that the source container group is still in a service state during the rescheduling and/or upgrading solution, which improves the performance of storage services and reduces the data unavailable time.

Abstract: A long-acting brexpiprazole preparation for injection and a preparation method therefor. The preparation method therefor comprises: (a) dissolving brexpiprazole in an organic solvent to form a brexpiprazole solution; (b1) pumping the brexpiprazole solution into a sheared or violently stirred precipitation solvent, so as to precipitate brexpiprazole, or (b2) pumping the precipitation solvent into the sheared or violently stirred brexpiprazole solution, so as to precipitate brexpiprazole; (c) filtering and optionally using water to wash an obtained solid; and (d1) drying the obtained solid, and respectively packaging the dried solid and an auxiliary material solution to obtain the long-acting brexpiprazole preparation for injection, or (d2) dispersing the obtained solid into the auxiliary material solution to obtain the long-acting brexpiprazole preparation for injection.

Abstract: Provided in the present application are an antibody-drug conjugate, and a preparation method therefor and the use thereof. The antibody drug conjugate has a structure as represented by the formula Ab-[M-L-E-D]x, and the drug is selected from an anti-tubulin agent, a DNA intercalator, a DNA topoisomerase inhibitor and a RNA polymerase inhibitor. The prepared antibody-drug conjugate has a better drug-to-antibody ratio, and has a good targeted killing effect on colon cancer and non-small cell lung cancer (for example, lung adenocarcinoma).

Abstract: A model training method and device are provided. The method is applied to an OAM entity and includes: obtaining at least one wireless access network device group by grouping a plurality of wireless access network devices sending model subscription requests, the wireless access network device group including a first number of wireless access network devices; determining a first number of model training structures corresponding to the first number of wireless access network devices, and determining a first number of unique model layers according to the first number of model training structures; and sending, to the first number of wireless access network devices, structural parameters of the first number of unique model layers.

Abstract: Methods for repurposing thermal hydrocarbon recovery operations where the reservoir, which has been previously treated with steam for hydrocarbon mobilization, is further treated with an oxidizer to induce one or more of thermal cracking (thermolysis), gasification, water-gas shift, and aquathermolysis reactions to generate synthesis gas within the reservoir, which synthesis gas or its constituent components can then be produced to surface.

Abstract: A method for transmitting indication information, includes: determining a discontinuous reception mode of a user equipment according to service data traffic and channel state information of the user equipment in a current discontinuous reception period; and transmitting first indication information to the user equipment, where the first indication information is used to indicate the discontinuous reception mode.

Abstract: The present invention relates to a chemical coupling linker and use thereof, and a bioactive conjugate prepared by the chemical coupling linker. The present invention also relates to use of the bioactive conjugate in the preparation of a drug for the prevention or treatment of tumor diseases.

Abstract: The present invention relates to the use of a medicament in treatment of a tumor disease. In particular, the present invention provides the use of a biologically active conjugate represented by formula (I) in treatment of a tumor disease. The tumor disease particularly and preferably refers to an unresectable locally advanced or metastatic solid tumor that is refractory according to existing treatment standards, including but not limited to breast cancer, gastric cancer, lung cancer, ovarian cancer, urinary tract epithelial cancer, esophageal cancer, liver cancer, colorectal cancer, cervical cancer, endometrial cancer, pancreatic cancer, and brain tumor.